Safety evaluation of aprepitant for the prevention of chemotherapy-induced nausea and vomiting

Bibliography

• Coates A, Abraham S, Kaye SB, On the receiving end–patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8
   PubMedGoogle Scholar
• de Boer-Dennert M, de WR, Schmitz PI, Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 1997;76:1055-61
   PubMed Web of Science ®Google Scholar
• Griffin AM, Butow PN, Coates AS, On the receiving end. V Patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7:189-95
   PubMed Web of Science ®Google Scholar
• Leibundgut U, Lancranjan I. First results with ICS 205-930 (5-HT3 receptor antagonist) in prevention of chemotherapy-induced emesis. Lancet 1987;1:1198
   PubMed Web of Science ®Google Scholar
• Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Italian group for antiemetic research. Lancet 1992;340:96-9
   PubMed Web of Science ®Google Scholar
• Hesketh PJ, Grunberg SM, Gralla RJ, The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003;21:4112-19
   PubMed Web of Science ®Google Scholar
• Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003;97:3090-8
   PubMed Web of Science ®Google Scholar
• Warr DG, Hesketh PJ, Gralla RJ, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 2005;23:2822-30
   PubMed Web of Science ®Google Scholar
• Rapoport BL, Jordan K, Boice JA, Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 2010;18:423-31
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Aapro MS, Poli-Bigelli S, Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 2006;17:1000-6
   PubMed Web of Science ®Google Scholar
• Majumdar AK, McCrea JB, Panebianco DL, Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther 2003;74:150-6
   PubMed Web of Science ®Google Scholar
• Sanchez RI, Wang RW, Newton DJ, Cytochrome P450 3A4 is the major enzyme involved in the metabolism of the substance P receptor antagonist aprepitant. Drug Metab Dispos 2004;32:1287-92
   PubMed Web of Science ®Google Scholar
• Shadle CR, Lee Y, Majumdar AK, Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol 2004;44:215-23
   PubMed Web of Science ®Google Scholar
• Peroutka SJ, Snyder SH. Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet 1982;1:658-9
   PubMed Web of Science ®Google Scholar
• Borison HL, McCarthy LE. Neuropharmacology of chemotherapy-induced emesis. Drugs 1983;25(Suppl 1):8-17
   PubMed Web of Science ®Google Scholar
• Carpenter DO, Briggs DB, Strominger N. Peptide-induced emesis in dogs. Behav Brain Res 1984;11:277-81
   PubMed Web of Science ®Google Scholar
• Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995;26:911-44
   PubMedGoogle Scholar
• Andrews PL, Bhandari P. Resinferatoxin, an ultrapotent capsaicin analogue, has anti-emetic properties in the ferret. Neuropharmacology 1993;32:799-806
   PubMed Web of Science ®Google Scholar
• Bountra C, Bunce K, Dale T, Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99,994, in ferrets. Eur J Pharmacol 1993;249:R3-4
   PubMed Web of Science ®Google Scholar
• Gardner CJ, Twissell DJ, Dale TJ, The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol 1995;116:3158-63
   PubMed Web of Science ®Google Scholar
• Minami M, Endo T, Yokota H, Effects of CP-99, 994, a tachykinin NK(1) receptor antagonist, on abdominal afferent vagal activity in ferrets: evidence for involvement of NK(1) and 5-HT(3) receptors. Eur J Pharmacol 2001;428:215-20
   PubMed Web of Science ®Google Scholar
• Snider RM, Constantine JW, Lowe JA III, A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 1991;251:435-7
   PubMed Web of Science ®Google Scholar
• Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG. The tachykinin NK1 receptor antagonist CP-99,994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 1993;250:R5-6
   PubMed Web of Science ®Google Scholar
• Madsen JL, Fuglsang S. A randomized, placebo-controlled, crossover, double-blind trial of the NK1 receptor antagonist aprepitant on gastrointestinal motor function in healthy humans. Aliment Pharmacol Ther 2008;27:609-15
   PubMed Web of Science ®Google Scholar
• Huskey SE, Dean BJ, Bakhtiar R, Brain penetration of aprepitant, a substance P receptor antagonist, in ferrets. Drug Metab Dispos 2003;31:785-91
   PubMed Web of Science ®Google Scholar
• Emend label. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory
   Google Scholar
• Wu Y, Loper A, Landis E, The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm 2004;285:135-46
   PubMed Web of Science ®Google Scholar
• Majumdar AK, Howard L, Goldberg MR, Pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers. J Clin Pharmacol 2006;46:291-300
   PubMed Web of Science ®Google Scholar
• Bergstrom M, Hargreaves RJ, Burns HD, Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant. Biol Psychiatry 2004;55:1007-12
   PubMed Web of Science ®Google Scholar
• Huskey SE, Dean BJ, Doss GA, The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs. Drug Metab Dispos 2004;32:246-58
   PubMed Web of Science ®Google Scholar
• Roila F, Herrstedt J, Aapro M, Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010;21(Suppl 5):v232-43
   PubMed Web of Science ®Google Scholar
• Bjornsson TD, Callaghan JT, Einolf HJ, The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003;43:443-69
   PubMed Web of Science ®Google Scholar
• Campos D, Pereira JR, Reinhardt RR, Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-67
   PubMed Web of Science ®Google Scholar
• Chawla SP, Grunberg SM, Gralla RJ, Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003;97:2290-300
   PubMed Web of Science ®Google Scholar
• Navari RM, Reinhardt RR, Gralla RJ, Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 antiemetic trials group. N Engl J Med 1999;340:190-5
   PubMed Web of Science ®Google Scholar
• Takahashi T, Hoshi E, Takagi M, Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci 2010; published online , doi:CAS1689 [pii];10.1111/j.1349-7006.2010.01689.x [doi]
   Google Scholar
• van Belle S, Lichinitser MR, Navari RM, Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer 2002;94:3032-41
   PubMed Web of Science ®Google Scholar
• de Wit R, Herrstedt J, Rapoport B, The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials. Eur J Cancer 2004;40:403-10
   PubMed Web of Science ®Google Scholar
• de Wit R, Herrstedt J, Rapoport B, Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003;21:4105-11
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Muss HB, Warr DG, Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer 2005;104:1548-55
   PubMed Web of Science ®Google Scholar
• de Jonge ME, Huitema AD, Holtkamp MJ, Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol 2005;56:370-8
   PubMed Web of Science ®Google Scholar
• Depre M, Van HA, Oeyen M, Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol 2005;61:341-6
   PubMed Web of Science ®Google Scholar
• Majumdar AK, Yan KX, Selverian DV, Effect of aprepitant on the pharmacokinetics of intravenous midazolam. J Clin Pharmacol 2007;47:744-50
   PubMed Web of Science ®Google Scholar
• McCrea JB, Majumdar AK, Goldberg MR, Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther 2003;74:17-24
   PubMed Web of Science ®Google Scholar
• Nakade S, Ohno T, Kitagawa J, Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting. Cancer Chemother Pharmacol 2008;63:75-83
   PubMed Web of Science ®Google Scholar
• Blum RA, Majumdar A, McCrea J, Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects. Clin Ther 2003;25:1407-19
   PubMed Web of Science ®Google Scholar
• Loos WJ, de WR, Freedman SJ, Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients. Cancer Chemother Pharmacol 2007;59:407-12
   PubMed Web of Science ®Google Scholar
• Nygren P, Hande K, Petty KJ, Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol 2005;55:609-16
   PubMed Web of Science ®Google Scholar
• Shah AK, Hunt TL, Gallagher SC, Cullen MT Jr. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Curr Med Res Opin 2005;21:595-601
   PubMed Web of Science ®Google Scholar
• Stoch SA, Gargano C, Valentine J, Double-blind crossover study to assess potential differences in cytochrome P450 3A4 activity in healthy subjects receiving ondansetron plus dexamethasone, with and without aprepitant. Cancer Chemother Pharmacol 2010; published online, doi:10.1007/s00280-010-1421-y
   Google Scholar
• Kivisto KT, Kroemer HK, Eichelbaum M. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. Br J Clin Pharmacol 1995;40:523-30
   PubMed Web of Science ®Google Scholar
• Howell JE, Szabatura AH, Hatfield SA, Nesbit SA. Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 2008;14:157-62
   PubMedGoogle Scholar
• Durand JP, Gourmel B, Mir O, Goldwasser F. Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy. Ann Oncol 2007;18:808-9
   PubMed Web of Science ®Google Scholar
• Ho H, Yuen C. Aprepitant-associated ifosfamide neurotoxicity. 16th edition. Sage Publications, Ltd; 2010. p. 137-8
   Google Scholar
• Jarkowski A III. Possible contribution of aprepitant to ifosfamide-induced neurotoxicity. Am J Health Syst Pharm 2008;65:2229-31
   PubMed Web of Science ®Google Scholar
• Jordan K, Kinitz I, Voigt W, Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy. Eur J Cancer 2009;45:1184-7
   PubMed Web of Science ®Google Scholar
• Feuring M, Lee Y, Orlowski LH, Lack of effect of aprepitant on digoxin pharmacokinetics in healthy subjects. J Clin Pharmacol 2003;43:912-17
   PubMed Web of Science ®Google Scholar
• Smith AR, Repka TL, Weigel BJ. Aprepitant for the control of chemotherapy induced nausea and vomiting in adolescents. Pediatr Blood Cancer 2005;45:857-60
   PubMed Web of Science ®Google Scholar
• Gore L, Chawla S, Petrilli A, Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability. Pediatr Blood Cancer 2009;52:242-7
   PubMed Web of Science ®Google Scholar
• Bergman AJ, Marbury T, Fosbinder T, Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin Pharmacokinet 2005;44:637-47
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Rolski J, Strausz J, Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:549-58
   PubMed Web of Science ®Google Scholar
• Herrstedt J, Apornwirat W, Shaharyar A, Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. J Clin Oncol 2009;27:5363-9
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Dugan M, Muss H, Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy. Support Care Cancer 2009;17:589-94
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Chua D, Devandry S, Evaluation of fosaprepitant in a single dose schedule for prevention of chemotherapy-induced nausea and vomiting: a phase III randomized double-blind study. Support Care Cancer 2010;18(Suppl 3):S79
   Google Scholar